Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8026750 | 0.78 | ALDH1A1 (0.65) | ALDH1A1GAAKDM4EKMT2AGLA | |
| SCHEMBL18751057 | 0.78 | ALDH1A1 (0.44) | ALDH1A1GAAKDM4EKMT2ANPC1 | |
| SCHEMBL30824519 | 0.77 | ALDH1A1 (0.49) | ALDH1A1GAAKDM4EKMT2ANPC1 | |
| SCHEMBL4744938 | 0.77 | TDP1 (0.53) | ALDH1A1GAAKDM4EKMT2ANPC1 | |
| SCHEMBL31105792 | 0.77 | ALDH1A1 (0.49) | ALDH1A1GAAKDM4EKMT2AGLA | |
| SCHEMBL31314315 | 0.77 | TDP1 (0.53) | ALDH1A1GAAKDM4EKMT2ANPC1 | |
| SCHEMBL3232438 | 0.77 | ALDH1A1 (0.49) | ALDH1A1GAAKDM4EKMT2AGLA | |
| SCHEMBL13405536 | 0.77 | ALDH1A1 (0.49) | ALDH1A1GAAKDM4EKMT2ANPC1 | |
| SCHEMBL28326811 | 0.77 | ALDH1A1 (0.49) | ALDH1A1GAAKDM4EKMT2ANPC1 | |
| SCHEMBL12116996 | 0.77 | ALDH1A1 (0.53) | ALDH1A1GAAKDM4EKMT2AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026072-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2018-05-11 | — | — | CN | disclosed |
| US-9073863-B2 | Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2699572-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012166654-A1 | CYANOQUINOLINE COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND INCREASING ION TRANSPORT AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012143143-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| EP-1885875-A2 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORPORATION (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006130551-A2 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | CFTR, SLC47A1, SLC47A2 | ALDH1A1 3445/4885GAA 570/4885KDM4E 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.